Bedinvetmab
Based on 1 Customer Validation
Bedinvetmab (ZTS-00508841) is a canine monoclonal antibody (mAb) targeting nerve growth factor (NGF). Bedinvetmab inhibits NGF interaction with tropomyosin receptor kinase A (trkA) and p75 neurotrophin receptor (p75NTR) receptors. Bedinvetmab can be used for the research of osteoarthritis pain in dogs.
For research use only. We do not sell to patients.
- Purity: 99.80%
- CAS No.: 2171034-69-6
- Molecular Weight:145.34 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Canine IgG2 lambda
Canine
Canlupfam NGF
Bedinvetmab (1 mg/kg; s.c. monthly; 3× and 10× dose multiples) is well tolerated in normal laboratory Beagle dogs for 6 months and with 2 weeks' concurrent NSAID administration[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Canlupfam NGF
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG2-lambda
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 2171034-69-6
-
Appearance Liquid
-
Molecular Weight 145.34 kDa
-
Color Colorless to light yellow
-
SMILES
[Bedinvetmab]
-
Synonyms
ZTS-00508841
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (256 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Corral MJ, et, al. A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis. Vet Anaesth Analg. 2021 Nov;48(6):943-955. [Content Brief]
[2]. Krautmann M, et, al. Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs. Vet J. 2021 Oct;276:105733. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Bedinvetmab Related Classifications
HY-P99297 Related Classifications
Powered by Bioz